SECTION 1. IDENTIFICATION

Product name : XOLAIR PFS 300mg/2ml

Product code : RO548-9789/F07

Common name(s), synonym(s) of the substance : XOLAIR 15% aqueous solution of Omalizumab with excipients for XOLAIR Sterile Liquid for injection
XOLAIR 15% aqueous solution of Omalizumab with excipients for XOLAIR PFS

Manufacturer or supplier’s details

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way
South San Francisco, CA 94080
USA

Telephone : 001-(650) 225-1000
E-mail address : info.sds@roche.com

Emergency telephone : US Chemtrec phone (800)-424-9300

Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance

Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omalizumab</td>
<td>242138-07-4</td>
<td>15.0</td>
</tr>
<tr>
<td>L-Arginine, hydrochloride (1:1)</td>
<td>1119-34-2</td>
<td>4.21</td>
</tr>
<tr>
<td>L-Histidine monohydrochloride mo-nohydrate</td>
<td>5934-29-2</td>
<td>0.23</td>
</tr>
<tr>
<td>L-Histidine</td>
<td>71-00-1</td>
<td>0.14</td>
</tr>
</tbody>
</table>
SECTION 4. FIRST AID MEASURES

General advice : Do not leave the victim unattended.

If inhaled : Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

In case of skin contact : If on skin, rinse well with water.

In case of eye contact : Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.

If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.

Most important symptoms and effects, both acute and delayed : None known.

Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Specific hazards during firefighting : No information available.

Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:
Carbon monoxide
Nitrogen oxides (NOx)
Sulfur oxides

Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.
SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Refer to protective measures listed in sections 7 and 8.

Environmental precautions: Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Wipe up with absorbent material (e.g. cloth, fleece). Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion: Normal measures for preventive fire protection.

Advice on safe handling: For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage: Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions: See label, package insert or internal guidelines.

Materials to avoid: No materials to be especially mentioned.

Storage temperature: Protected from heat and light.

Further information on storage stability: No decomposition if stored and applied as directed.

Packaging material: Suitable material: glass, glass bottles, Prefilled syringes.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omalizumab</td>
<td>242138-07-4</td>
<td>IOEL</td>
<td>0.02 mg/m3</td>
<td>Roche Industrial Hygiene Com-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mittee (RiHC)</td>
</tr>
</tbody>
</table>

Engineering measures: No data available.

Personal protective equipment

Respiratory protection: No personal respiratory protective equipment normally required.
Hand protection

In case of contact through splashing:

Material: Nitrile rubber
Break through time: > 30 min
Glove thickness: > 0.11 mm

In case of full contact:

Material: butyl-rubber
Break through time: > 480 min
Glove thickness: > 0.4 mm

Remarks: Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection: Safety glasses

Skin and body protection: Protective suit

Hygiene measures: Handle in accordance with good industrial hygiene and safety practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: Aqueous solution, Clear liquid, sterile

Color: No data available

Odor: No data available

Odor Threshold: No data available

pH: 6.0

Melting point/range: No data available

Boiling point/boiling range: No data available

Flash point: does not flash

Evaporation rate: No data available

Flammability (solid, gas): Does not sustain combustion.

Flammability (liquids): Does not sustain combustion.

Self-ignition: Not applicable

Upper explosion limit / Upper flammability limit: No data available
SECTION 10. STABILITY AND REACTIVITY

Reactivity: No dangerous reaction known under conditions of normal use.

Chemical stability: Stable under normal conditions. Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created.

Possibility of hazardous reactions: Stable under recommended storage conditions. No hazards to be specially mentioned.

Conditions to avoid: No data available

Incompatible materials: No data available

Hazardous decomposition products: No data available

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity
Not classified based on available information.
Components:

Omalizumab:

Acute oral toxicity: Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration): LD0 (Monkey): 200 mg/kg Application Route: i.v.

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:

Omalizumab:

Genotoxicity in vitro: Test Type: Ames test
Test system: Salmonella typhimurium
Metabolic activation: with and without metabolic activation
Result: negative

Carcinogenicity
Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Not classified based on available information.

Components:

Omalizumab:

Effects on fetal development: Species: cynomolgus monkey, female
Application Route: s.c.
General Toxicity Maternal: NOAEL: 75 mg/kg bw/day
Embryo-fetal toxicity: NOAEL: 75 mg/kg bw/day
Result: No adverse effects.
STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:
Omalizumab:
Species: cynomolgus monkey
LOEL: 30 mg/kg/w
Application Route: s.c.
Exposure time: 26 Weeks

Aspiration toxicity
Not classified based on available information.

Further information

Components:
Omalizumab:
Remarks: anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity
No data available

Persistence and degradability

Components:
Omalizumab:
Biodegradability: Result: Globular proteins are generally well biodegradable

Bioaccumulative potential

Components:
Omalizumab:
Partition coefficient: n-octanol/water: Remarks: No data available

Mobility in soil
No data available

Other adverse effects

Product:
Ozone-Depletion Potential: Regulation: 40 CFR Protection of Environment; Part 82 Pro-
SAFETY DATA SHEET

XOLAIR PFS 300mg/2ml

Components:

Omalizumab:

Additional ecological information: Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected.

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues: Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable

Domestic regulation

49 CFR
Not regulated as a dangerous good

Special precautions for user

Remarks: Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.
SAFETY DATA SHEET

XOLAIR PFS 300mg/2ml

Version 1.1
Revision Date: 11-08-2022
Date of last issue: 01-30-2020
Date of first issue: 01-30-2020

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Clean Air Act
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act
This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.
This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307.
This product does not contain any priority pollutants related to the U.S. Clean Water Act.

US State Regulations

Massachusetts Right To Know
No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know
Water 7732-18-5
Omalizumab 242138-07-4
L-Arginine, hydrochloride (1:1) 1119-34-2

Maine Chemicals of High Concern
Product does not contain any listed chemicals

Vermont Chemicals of High Concern
Product does not contain any listed chemicals

Washington Chemicals of High Concern
Product does not contain any listed chemicals

The ingredients of this product are reported in the following inventories:
AIIC : Not in compliance with the inventory

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.
Omalizumab
L-Histidine monohydrochloride monohydrate

NZIoC: On the inventory, or in compliance with the inventory
ENCS: Not in compliance with the inventory
ISHL: Not in compliance with the inventory
KECI: Not in compliance with the inventory
PICCS: Not in compliance with the inventory
IECSC: Not in compliance with the inventory
TCSI: Not in compliance with the inventory
TSCA: Product contains substance(s) not listed on TSCA inventory.
TECI: Not in compliance with the inventory

TSCA list
No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

NFPA 704:

HMIS® IV:

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations
SAFETY DATA SHEET

XOLAIR PFS 300mg/2ml

Version 1.1
Revision Date: 11-08-2022
Date of last issue: 01-30-2020
Date of first issue: 01-30-2020

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2104